Furin-mediated protein processing in infectious diseases and cancer

Clinical and Translational Immunology

Volumn 8, Issue 8, 2019, Pages

  Braun, Elisabeth ^a   Sauter, Daniel ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

bacterial toxins; cancer; furin; guanylate binding proteins; proprotein convertases; viral glycoproteins

Indexed keywords

BACTERIAL TOXIN; EXOTOXIN; FURIN; GBP2 PROTEIN; GBP5 PROTEIN; PAR1 PROTEIN; SERINE PROTEINASE; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRUS GLYCOPROTEIN;

CANCER GROWTH; CARCINOGENESIS; EBOLAVIRUS; FLAVIVIRUS; HEPATITIS B VIRUS; HIGHLY PATHOGENIC AVIAN INFLUENZA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION; INFLUENZA A VIRUS; LIFE CYCLE; MALIGNANT NEOPLASM; MAMMAL; MARBURGVIRUS; NONHUMAN; PAPILLOMAVIRIDAE; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW;

EID: 85079563205     PISSN: None     EISSN: 20500068     Source Type: Journal    
DOI: 10.1002/cti2.1073     Document Type: Review

References (144)

1. Chakraborti S, Dhalla NS. Pathophysiological Aspects of Proteases. Berlin, Germany: Springer, 2017.
2. Tian S, Huang Q, Fang Y et al. FurinDB: a database of 20-residue furin cleavage site motifs, substrates and their associated drugs. Int J Mol Sci 2011; 12: 1060–1065.
3. Steiner DF, Cunningham D, Spigelman L et al. Insulin biosynthesis: evidence for a precursor. Science 1967; 157: 697–700.
4. Roebroek AJ, Schalken JA, Leunissen JA et al. Evolutionary conserved close linkage of the c-fes/fps proto-oncogene and genetic sequences encoding a receptor-like protein. EMBO J 1986; 5: 2197–2202.
5. van de Ven WJ, Voorberg J, Fontijn R et al. Furin is a subtilisin-like proprotein processing enzyme in higher eukaryotes. Mol Biol Rep 1990; 14: 265–275.
6. Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012; 11: 367–383.
7. Cheng D, Espenshade PJ, Slaughter CA et al. Secreted site-1 protease cleaves peptides corresponding to luminal loop of sterol regulatory element-binding proteins. J Biol Chem 1999; 274: 22805–22812.
8. McNutt MC, Lagace TA, Horton JD. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem 2007; 282: 20799–20803.
9. Uhlén M, Fagerberg L, Hallström BM et al. Tissue-based map of the human proteome. Science 2015; 347: 1260419.
10. Ayoubi TA, Creemers JW, Roebroek AJ et al. Expression of the dibasic proprotein processing enzyme furin is directed by multiple promoters. J Biol Chem 1994; 269: 9298–9303.
11. Pesu M, Muul L, Kanno Y et al. Proprotein convertase furin is preferentially expressed in T helper 1 cells and regulates interferon γ. Blood 2006; 108: 983–985.
12. Blanchette F, Day R, Dong W et al. TGFβ1 regulates gene expression of its own converting enzyme furin. J Clin Invest 1997; 99: 1974–1983.
13. Decroly E, Vandenbranden M, Ruysschaert JM et al. The convertases furin and PC1 can both cleave the human immunodeficiency virus (HIV)-1 envelope glycoprotein gp160 into gp120 (HIV-1 SU) and gp41 (HIV-I TM). J Biol Chem 1994; 269: 12240–12247.
14. Hipp MM, Shepherd D, Gileadi U et al. Processing of human toll-like receptor 7 by furin-like proprotein convertases is required for its accumulation and activity in endosomes. Immunity 2013; 39: 711–721.
15. Shinde U, Inouye M. Intramolecular chaperones and protein folding. Trends Biochem Sci 1993; 18: 442–446.
16. Anderson ED, VanSlyke JK, Thulin CD et al. Activation of the furin endoprotease is a multiple-step process: requirements for acidification and internal propeptide cleavage. EMBO J 1997; 16: 1508–1518.
17. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002; 3: 753–766.
18. Molloy SS, Thomas L, VanSlyke JK et al. Intracellular trafficking and activation of the furin proprotein convertase: localization to the TGN and recycling from the cell surface. EMBO J 1994; 13: 18–33.
19. Vey M, Schäfer W, Berghöfer S et al. Maturation of the trans-Golgi network protease furin: compartmentalization of propeptide removal, substrate cleavage, and COOH-terminal truncation. J Cell Biol 1994; 127: 1829–1842.
20. Plaimauer B, Mohr G, Wernhart W et al. “Shed” furin: mapping of the cleavage determinants and identification of its C-terminus. Biochem J 2001; 354: 689–695.
21. Tian S. A 20 Residues motif delineates the furin cleavage site and its physical properties may influence viral fusion. Biochem Insights 2009; 2: BCI.S2049.
22. Jin W, Fuki IV, Seidah NG et al. Proprotein convertases [corrected] are responsible for proteolysis and inactivation of endothelial lipase. J Biol Chem 2005; 280: 36551–36559.
23. Essalmani R, Susan-Resiga D, Chamberland A et al. In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem 2011; 286: 4257–4263.
24. Roebroek AJ, Umans L, Pauli IG et al. Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase Furin. Development 1998; 125: 4863–4876.
25. Kim W, Essalmani R, Szumska D et al. Loss of endothelial furin leads to cardiac malformation and early postnatal death. Mol Cell Biol 2012; 32: 3382–3391.
26. Chen Y, Molloy SS, Thomas L et al. Mutations within a furin consensus sequence block proteolytic release of ectodysplasin-A and cause X-linked hypohidrotic ectodermal dysplasia. Proc Natl Acad Sci USA 2001; 98: 7218–7223.
27. Giannelli F, Green PM, High KA et al. Haemophilia B: database of point mutations and short additions and deletions. Nucleic Acids Res 1990; 18: 4053–4059.
28. Bassi DE, Fu J, Lopez de Cicco R et al. Proprotein convertases: “master switches” in the regulation of tumor growth and progression. Mol Carcinog 2005; 44: 151–161.
29. Klein-Szanto AJ, Bassi DE. Proprotein convertase inhibition: paralyzing the cell's master switches. Biochem Pharmacol 2017; 140: 8–15.
30. Jaaks P, Bernasconi M. The proprotein convertase furin in tumour progression: the PC furin in tumour progression. Int J Cancer 2017; 141: 654–663.
31. McMahon S, Grondin F, McDonald PP et al. Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins. J Biol Chem 2005; 280: 6561–6569.
32. Arsenault D, Lucien F, Dubois CM. Hypoxia enhances cancer cell invasion through relocalization of the proprotein convertase furin from the trans-Golgi network to the cell surface. J Cell Physiol 2012; 227: 789–800.
33. Stupack DG, Cheresh DA. Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 2002; 115: 3729–3738.
34. Dahmani A, Delisle J-S. TGF-β in T cell biology: implications for cancer immunotherapy. Cancers 2018; 10: 194.
35. Pesu M, Watford WT, Wei L et al. T cell-expressed proprotein convertase furin is essential for maintenance of peripheral tolerance. Nature 2008; 455: 246–250.
36. Bourne GL, Grainger DJ. Development and characterisation of an assay for furin activity. J Immunol Methods 2011; 364: 101–108.
37. Mojic M, Takeda K, Hayakawa Y. The dark side of IFN-γ: its role in promoting cancer immunoevasion. Int J Mol Sci 2017; 19: 89.
38. Lee M, Ryu CH, Chang HW et al. Radiotherapy-associated furin expression and tumor invasiveness in recurrent laryngeal cancer. Anticancer Res 2016; 36: 5117–5125.
39. Gordon VM, Leppla SH. Proteolytic activation of bacterial toxins: role of bacterial and host cell proteases. Infect Immun 1994; 62: 333–340.
40. Tsuneoka M, Nakayama K, Hatsuzawa K et al. Evidence for involvement of furin in cleavage and activation of diphtheria toxin. J Biol Chem 1993; 268: 26461–26465.
41. Ogata M, Fryling CM, Pastan I et al. Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. J Biol Chem 1992; 267: 25396–25401.
42. Collier RJ. Effect of diphtheria toxin on protein synthesis: inactivation of one of the transfer factors. J Mol Biol 1967; 25: 83–98.
43. Williams DP, Wen Z, Watson RS et al. Cellular processing of the interleukin-2 fusion toxin DAB486-IL-2 and efficient delivery of diphtheria fragment A to the cytosol of target cells requires Arg194. J Biol Chem 1990; 265: 20673–20677.
44. Molloy SS, Bresnahan PA, Leppla SH et al. Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J Biol Chem 1992; 267: 16396–16402.
45. Wagner PL, Waldor MK. Bacteriophage control of bacterial virulence. Infect Immun 2002; 70: 3985–3993.
46. Klenk HD, Garten W. Host cell proteases controlling virus pathogenicity. Trends Microbiol 1994; 2: 39–43.
47. Nagai Y, Hamaguchi M, Toyoda T. Molecular biology of Newcastle disease virus. Prog Vet Microbiol Immunol 1989; 5: 16–64.
48. Klenk HD, Rott R. The molecular biology of influenza virus pathogenicity. Adv Virus Res 1988; 34: 247–281.
49. Moulard M, Decroly E. Maturation of HIV envelope glycoprotein precursors by cellular endoproteases. Biochim Biophys Acta 2000; 1469: 121–132.
50. Fenouillet E, Gluckman JC. Immunological analysis of human immunodeficiency virus type 1 envelope glycoprotein proteolytic cleavage. Virology 1992; 187: 825–828.
51. Kieny MP, Lathe R, Rivière Y et al. Improved antigenicity of the HIV env protein by cleavage site removal. Protein Eng 1988; 2: 219–225.
52. Okumura Y, Yano M, Murakami M et al. The extracellular processing of HIV-1 envelope glycoprotein gp160 by human plasmin. FEBS Lett 1999; 442: 39–42.
53. Tashiro M, Ciborowski P, Klenk H-D et al. Role of Staphylococcus protease in the development of influenza pneumonia. Nature 1987; 325: 536.
54. Garten W, Braden C, Arendt A et al. Influenza virus activating host proteases: identification, localization and inhibitors as potential therapeutics. Eur J Cell Biol 2015; 94: 375–383.
55. Böttcher E, Matrosovich T, Beyerle M et al. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J Virol 2006; 80: 9896–9898.
56. Stieneke-Gröber A, Vey M, Angliker H et al. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J 1992; 11: 2407–2414.
57. Horimoto T, Nakayama K, Smeekens SP et al. Proprotein-processing endoproteases PC6 and furin both activate hemagglutinin of virulent avian influenza viruses. J Virol 1994; 68: 6074–6078.
58. Perdue ML, García M, Senne D et al. Virulence-associated sequence duplication at the hemagglutinin cleavage site of avian influenza viruses. Virus Res 1997; 49: 173–186.
59. Röhm C, Süss J, Pohle V et al. Different hemagglutinin cleavage site variants of H7N7 in an influenza outbreak in chickens in Leipzig, Germany. Virology 1996; 218: 253–257.
60. Ohuchi M, Orlich M, Ohuchi R et al. Mutations at the cleavage site of the hemagglutinin alter the pathogenicity of influenza virus a/chick/penn/83 (H5N2). Virology 1989; 168: 274–280.
61. Baron J, Tarnow C, Mayoli-Nüssle D et al. Matriptase, HAT, and TMPRSS2 activate the hemagglutinin of H9N2 influenza A viruses. J Virol 2013; 87: 1811–1820.
62. Tse LV, Hamilton AM, Friling T et al. A novel activation mechanism of avian influenza virus H9N2 by furin. J Virol 2014; 88: 1673–1683.
63. Volchkov VE, Feldmann H, Volchkova VA et al. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci USA 1998; 95: 5762–5767.
64. Volchkov VE, Volchkova VA, Ströher U et al. Proteolytic processing of Marburg virus glycoprotein. Virology 2000; 268: 1–6.
65. Wool-Lewis RJ, Bates P. Endoproteolytic processing of the Ebola virus envelope glycoprotein: cleavage is not required for function. J Virol 1999; 73: 1419–1426.
66. Neumann G, Geisbert TW, Ebihara H et al. Proteolytic processing of the Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates. J Virol 2007; 81: 2995–2998.
67. Volchkov VE, Becker S, Volchkova VA et al. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 1995; 214: 421–430.
68. Volchkova VA, Klenk HD, Volchkov VE. ∆-peptide is the carboxy-terminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus. Virology 1999; 265: 164–171.
69. de la Vega M-A, Wong G, Kobinger GP et al. The multiple roles of sGP in Ebola pathogenesis. Viral Immunol 2015; 28: 3–9.
70. Pierson TC, Diamond MS. Degrees of maturity: the complex structure and biology of flaviviruses. Curr Opin Virol 2012; 2: 168–175.
71. Guirakhoo F, Heinz FX, Mandl CW et al. Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions. J Gen Virol 1991; 72: 1323–1329.
72. Yu I-M, Zhang W, Holdaway HA et al. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 2008; 319: 1834–1837.
73. Yu I-M, Holdaway HA, Chipman PR et al. Association of the pr peptides with dengue virus at acidic pH blocks membrane fusion. J Virol 2009; 83: 12101–12107.
74. Elshuber S, Allison SL, Heinz FX et al. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J Gen Virol 2003; 84: 183–191.
75. Zybert IA, van der Ende-Metselaar H, Wilschut J et al. Functional importance of dengue virus maturation: infectious properties of immature virions. J Gen Virol 2008; 89: 3047–3051.
76. Davis CW, Nguyen H-Y, Hanna SL et al. West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol 2006; 80: 1290–1301.
77. Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM et al. Immature dengue virus: a veiled pathogen? PLoS Pathog 2010; 6: e1000718.
78. Junjhon J, Lausumpao M, Supasa S et al. Differential modulation of prM cleavage, extracellular particle distribution, and virus infectivity by conserved residues at nonfurin consensus positions of the dengue virus pr-M junction. J Virol 2008; 82: 10776–10791.
79. Richards RM, Lowy DR, Schiller JT et al. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci USA 2006; 103: 1522–1527.
80. Day PM, Schiller JT. The role of furin in papillomavirus infection. Future Microbiol 2009; 4: 1255–1262.
81. Day PM, Gambhira R, Roden RBS et al. Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol 2008; 82: 4638–4646.
82. Ito K, Kim K-H, Lok AS-F et al. Characterization of genotype-specific carboxyl-terminal cleavage sites of hepatitis B virus e antigen precursor and identification of furin as the candidate enzyme. J Virol 2009; 83: 3507–3517.
83. Messageot F, Salhi S, Eon P et al. Proteolytic processing of the hepatitis B virus e antigen precursor. Cleavage at two furin consensus sequences. J Biol Chem 2003; 278: 891–895.
84. Milich DR, Chen MK, Hughes JL et al. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 1998; 160: 2013–2021.
85. Chen MT, Billaud J-N, Sällberg M et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci USA 2004; 101: 14913–14918.
86. Schlicht HJ, Schaller H. The secretory core protein of human hepatitis B virus is expressed on the cell surface. J Virol 1989; 63: 5399–5404.
87. Lei RX, Shi H, Peng XM et al. Influence of a single nucleotide polymorphism in the P1 promoter of the furin gene on transcription activity and hepatitis B virus infection. Hepatology 2009; 50: 763–771.
88. Daugherty MD, Malik HS. Rules of engagement: molecular insights from host-virus arms races. Annu Rev Genet 2012; 46: 677–700.
89. Lahouassa H, Daddacha W, Hofmann H et al. SAMHD1 restricts HIV-1 by reducing the intracellular pool of deoxynucleotide triphosphates. Nat Immunol 2012; 13: 223–228.
90. Gariano GR, Dell'Oste V, Bronzini M et al. The intracellular DNA sensor IFI16 gene acts as restriction factor for human cytomegalovirus replication. PLoS Pathog 2012; 8: e1002498.
91. Aerts L, Hamelin M-È, Rhéaume C et al. Modulation of protease activated receptor 1 influences human metapneumovirus disease severity in a mouse model. PLoS ONE 2013; 8: e72529.
92. Kim W, Zekas E, Lodge R et al. Neuroinflammation-induced interactions between protease-activated receptor 1 and proprotein convertases in HIV-associated neurocognitive disorder. Mol Cell Biol 2015; 35: 3684–3700.
93. Sachan V, Lodge R, Mihara K et al. HIV-induced neuroinflammation: impact of PAR1 and PAR2 processing by Furin. Cell Death Differ 2019.
94. McLaren PJ, Gawanbacht A, Pyndiah N et al. Identification of potential HIV restriction factors by combining evolutionary genomic signatures with functional analyses. Retrovirology 2015; 12: 41.
95. Krapp C, Hotter D, Gawanbacht A et al. Guanylate Binding Protein (GBP) 5 is an interferon-inducible inhibitor of HIV-1 infectivity. Cell Host Microbe 2016; 19: 504–514.
96. Braun E, Hotter D, Koepke L et al. Guanylate-Binding Proteins 2 and 5 exert broad antiviral activity by inhibiting furin-mediated processing of viral envelope proteins. Cell Rep 2019; 27: 2092–2104. e10.
97. Wang Q, Wang X, Liang Q et al. Distinct prognostic value of mRNA expression of guanylate-binding protein genes in skin cutaneous melanoma. Oncol Lett 2018; 15: 7914–7922.
98. Godoy P, Cadenas C, Hellwig B et al. Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response. Breast Cancer 2014; 21: 491–499.
99. Anderson ED, Thomas L, Hayflick JS et al. Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed α 1-antitrypsin variant. J Biol Chem 1993; 268: 24887–24891.
100. Watanabe M, Hirano A, Stenglein S et al. Engineered serine protease inhibitor prevents furin-catalyzed activation of the fusion glycoprotein and production of infectious measles virus. J Virol 1995; 69: 3206–3210.
101. Strongin A, Lebl M, Day R. Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens. 2009.
102. Cameron A, Appel J, Houghten RA et al. Polyarginines are potent furin inhibitors. J Biol Chem 2000; 275: 36741–36749.
103. Zhong M, Munzer JS, Basak A et al. The prosegments of furin and PC7 as potent inhibitors of proprotein convertases. In vitro and ex vivo assessment of their efficacy and selectivity. J Biol Chem 1999; 274: 33913–33920.
104. Lapierre M, Siegfried G, Scamuffa N et al. Opposing function of the proprotein convertases furin and PACE4 on breast cancer cells’ malignant phenotypes: role of tissue inhibitors of metalloproteinase-1. Cancer Res 2007; 67: 9030–9034.
105. Sarac MS, Cameron A, Lindberg I. The furin inhibitor hexa-D-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo. Infect Immun 2002; 70: 7136–7139.
106. Karicherla P, Hobden JA. Nona-D-arginine therapy for Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 2009; 50: 256–262.
107. Karicherla P, Hobden JA. Nona-D-arginine amide for prophylaxis and treatment of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res 2010; 35: 220–224.
108. Becker GL, Sielaff F, Than ME et al. Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. J Med Chem 2010; 53: 1067–1075.
109. Henrich S, Cameron A, Bourenkov GP et al. The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nat Struct Biol 2003; 10: 520–526.
110. Couture F, Kwiatkowska A, Dory YL et al. Therapeutic uses of furin and its inhibitors: a patent review. Expert Opin Ther Pat 2015; 25: 379–396.
111. Jiao G-S, Cregar L, Goldman ME et al. Guanidinylated 2,5-dideoxystreptamine derivatives as anthrax lethal factor inhibitors. Bioorg Med Chem Lett 2006; 16: 1527–1531.
112. Dahms SO, Jiao G-S, Than ME. Structural studies revealed active site distortions of human furin by a small molecule inhibitor. ACS Chem Biol 2017; 12: 1211–1216.
113. Garten W, Stieneke A, Shaw E et al. Inhibition of proteolytic activation of influenza virus hemagglutinin by specific peptidyl chloroalkyl ketones. Virology 1989; 172: 25–31.
114. Zhu J, Declercq J, Roucourt B et al. Generation and characterization of non-competitive furin-inhibiting nanobodies. Biochem J 2012; 448: 73–82.
115. Cui X, Mino T, Yoshinaga M et al. Regnase-1 and roquin nonredundantly regulate th1 differentiation causing cardiac inflammation and fibrosis. J Immunol 2017; 199: 4066–4077.
116. Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma - Full Text View - ClinicalTrials.gov.
117. Inaba K, Inaba M, Romani N et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176: 1693–1702.
118. Dubois CM, Laprise MH, Blanchette F et al. Processing of transforming growth factor β 1 precursor by human furin convertase. J Biol Chem 1995; 270: 10618–10624.
119. Yamaguchi Y, Tsumura H, Miwa M et al. Contrasting effects of TGF-β1 and TNF-α on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 1997; 15: 144–153.
120. ® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. Gynecol Oncol 2016; 143: 504–510.
121. Spaete RR, Thayer RM, Probert WS et al. Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology 1988; 167: 207–225.
122. Keller PM, Davison AJ, Lowe RS et al. Identification and structure of the gene encoding gpII, a major glycoprotein of varicella-zoster virus. Virology 1986; 152: 181–191.
123. Gong M, Ooka T, Matsuo T et al. Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB. J Virol 1987; 61: 499–508.
124. Cavanagh D, Davis PJ, Pappin DJ et al. Coronavirus IBV: partial amino terminal sequencing of spike polypeptide S2 identifies the sequence Arg-Arg-Phe-Arg-Arg at the cleavage site of the spike precursor propolypeptide of IBV strains Beaudette and M41. Virus Res 1986; 4: 133–143.
125. de Haan CAM, Stadler K, Godeke G-J et al. Cleavage inhibition of the murine coronavirus spike protein by a furin-like enzyme affects cell-cell but not virus-cell fusion. J Virol 2004; 78: 6048–6054.
126. Rice CM, Lenches EM, Eddy SR et al. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 1985; 229: 726–733.
127. Stadler K, Allison SL, Schalich J et al. Proteolytic activation of tick-borne encephalitis virus by furin. J Virol 1997; 71: 8475–8481.
128. Rice CM, Strauss JH. Nucleotide sequence of the 26S mRNA of Sindbis virus and deduced sequence of the encoded virus structural proteins. Proc Natl Acad Sci USA 1981; 78: 2062–2066.
129. Zhang X, Fugère M, Day R et al. Furin processing and proteolytic activation of Semliki Forest virus. J Virol 2003; 77: 2981–2989.
130. Gonzalez-Dunia D, Cubitt B, de la Torre JC. Mechanism of Borna disease virus entry into cells. J Virol 1998; 72: 783–788.
131. Richt JA, Fürbringer T, Koch A et al. Processing of the Borna disease virus glycoprotein gp94 by the subtilisin-like endoprotease furin. J Virol 1998; 72: 4528–4533.
132. Sanchez AJ, Vincent MJ, Erickson BR et al. Crimean-Congo hemorrhagic fever virus glycoprotein precursor is cleaved by Furin-like and SKI-1 proteases to generate a novel 38-kilodalton glycoprotein. J Virol 2006; 80: 514–525.
133. Kawaoka Y, Nestorowicz A, Alexander DJ et al. Molecular analyses of the hemagglutinin genes of H5 influenza viruses: origin of a virulent turkey strain. Virology 1987; 158: 218–227.
134. Porter AG, Barber C, Carey NH et al. Complete nucleotide sequence of an influenza virus haemagglutinin gene from cloned DNA. Nature 1979; 282: 471–477.
135. Toyoda T, Sakaguchi T, Imai K et al. Structural comparison of the cleavage-activation site of the fusion glycoprotein between virulent and avirulent strains of Newcastle disease virus. Virology 1987; 158: 242–247.
136. Spriggs MK, Olmsted RA, Venkatesan S et al. Fusion glycoprotein of human parainfluenza virus type 3: nucleotide sequence of the gene, direct identification of the cleavage-activation site, and comparison with other paramyxoviruses. Virology 1986; 152: 241–251.
137. Waxham MN, Server AC, Goodman HM et al. Cloning and sequencing of the mumps virus fusion protein gene. Virology 1987; 159: 381–388.
138. Richardson C, Hull D, Greer P et al. The nucleotide sequence of the mRNA encoding the fusion protein of measles virus (Edmonston strain): a comparison of fusion proteins from several different paramyxoviruses. Virology 1986; 155: 508–523.
139. Paterson RG, Harris TJ, Lamb RA. Fusion protein of the paramyxovirus simian virus 5: nucleotide sequence of mRNA predicts a highly hydrophobic glycoprotein. Proc Natl Acad Sci USA 1984; 81: 6706–6710.
140. Collins PL, Huang YT, Wertz GW. Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus. Proc Natl Acad Sci USA 1984; 81: 7683–7687.
141. McCune JM, Rabin LB, Feinberg MB et al. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 1988; 53: 55–67.
142. Grandgenett D, Quinn T, Hippenmeyer PJ et al. Structural characterization of the avian retrovirus reverse transcriptase and endonuclease domains. J Biol Chem 1985; 260: 8243–8249.
143. Freed EO, Risser R. The role of envelope glycoprotein processing in murine leukemia virus infection. J Virol 1987; 61: 2852–2856.
144. Geiselhart V, Bastone P, Kempf T et al. Furin-mediated cleavage of the feline foamy virus Env leader protein. J Virol 2004; 78: 13573–13581.